In this study, we reported for the first time that PKM2-c-Myc-survivin signaling cascade promoted breast cancer cell proliferation, migration, tamoxifen resistance (Figure 6H), and inhibition of PKM2 not only blocked cancer progression, but also enhanced tamoxifen efficacy in MCF-7 and MCF-7 resistant cells. This evidence concerns the gene BIRC5 and breast cancer.